LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 3 von insgesamt 3

Suchoptionen

  1. Artikel ; Online: Integrated Multi-Omics Analysis for Inferring Molecular Players in Inclusion Body Myositis

    Cantó-Santos, Judith / Valls-Roca, Laura / Tobías, Ester / Oliva, Clara / García-García, Francesc Josep / Guitart-Mampel, Mariona / Andújar-Sánchez, Félix / Esteve-Codina, Anna / Martín-Mur, Beatriz / Padrosa, Joan / Aránega, Raquel / Moreno-Lozano, Pedro J. / Milisenda, José César / Artuch, Rafael / Grau-Junyent, Josep M. / Garrabou, Glòria

    Antioxidants. 2023 Aug. 19, v. 12, no. 8

    2023  

    Abstract: Inclusion body myositis (IBM) is an acquired inflammatory myopathy affecting proximal and distal muscles that leads to weakness in patients over 50. It is diagnosed based on clinical and histological findings in muscle related to inflammation, ... ...

    Abstract Inclusion body myositis (IBM) is an acquired inflammatory myopathy affecting proximal and distal muscles that leads to weakness in patients over 50. It is diagnosed based on clinical and histological findings in muscle related to inflammation, degeneration, and mitochondria. In relation to IBM, a shortage of validated disease models and a lack of biomarkers and effective treatments constitute an unmet medical need. To overcome these hurdles, we performed an omics analysis of multiple samples from IBM patients (saliva, fibroblasts, urine, plasma, and muscle) to gain insight into the pathophysiology of IBM. Degeneration was evident due to the presence of amyloid β peptide 1–42 (Aβ1–42) in the saliva of the analyzed IBM patients. The presence of metabolic disarrangements in IBM was indicated by an imbalanced organic acid profile in fibroblasts and urine. Specifically, abnormal levels of L-pyroglutamic and orotic acid were supported by the abnormal expression of related metabolites in plasma and urine (glutathione and pyrimidines) and the aberrant expression of upstream gene regulators (L2HGDH, IDH2, OPLAH, and ASL) in muscle. Combined levels of L-pyroglutamic and orotic acid displayed an outstanding biomarker signature in urine with 100% sensitivity and specificity. The confirmation of systemic metabolic disarrangements in IBM and the identification of novel biomarkers reported herein unveil novel insights that require validation in larger cohorts.
    Schlagwörter amyloid ; biomarkers ; fibroblasts ; genes ; glutathione ; histology ; inflammation ; metabolites ; mitochondria ; multiomics ; muscles ; myositis ; orotic acid ; pathophysiology ; pyrimidines ; saliva ; urine
    Sprache Englisch
    Erscheinungsverlauf 2023-0819
    Erscheinungsort Multidisciplinary Digital Publishing Institute
    Dokumenttyp Artikel ; Online
    ZDB-ID 2704216-9
    ISSN 2076-3921
    ISSN 2076-3921
    DOI 10.3390/antiox12081639
    Datenquelle NAL Katalog (AGRICOLA)

    Zusatzmaterialien

    Kategorien

  2. Artikel: Integrated Multi-Omics Analysis for Inferring Molecular Players in Inclusion Body Myositis.

    Cantó-Santos, Judith / Valls-Roca, Laura / Tobías, Ester / Oliva, Clara / García-García, Francesc Josep / Guitart-Mampel, Mariona / Andújar-Sánchez, Félix / Esteve-Codina, Anna / Martín-Mur, Beatriz / Padrosa, Joan / Aránega, Raquel / Moreno-Lozano, Pedro J / Milisenda, José César / Artuch, Rafael / Grau-Junyent, Josep M / Garrabou, Glòria

    Antioxidants (Basel, Switzerland)

    2023  Band 12, Heft 8

    Abstract: Inclusion body myositis (IBM) is an acquired inflammatory myopathy affecting proximal and distal muscles that leads to weakness in patients over 50. It is diagnosed based on clinical and histological findings in muscle related to inflammation, ... ...

    Abstract Inclusion body myositis (IBM) is an acquired inflammatory myopathy affecting proximal and distal muscles that leads to weakness in patients over 50. It is diagnosed based on clinical and histological findings in muscle related to inflammation, degeneration, and mitochondria. In relation to IBM, a shortage of validated disease models and a lack of biomarkers and effective treatments constitute an unmet medical need. To overcome these hurdles, we performed an omics analysis of multiple samples from IBM patients (saliva, fibroblasts, urine, plasma, and muscle) to gain insight into the pathophysiology of IBM. Degeneration was evident due to the presence of amyloid β peptide 1-42 (Aβ1-42) in the saliva of the analyzed IBM patients. The presence of metabolic disarrangements in IBM was indicated by an imbalanced organic acid profile in fibroblasts and urine. Specifically, abnormal levels of L-pyroglutamic and orotic acid were supported by the abnormal expression of related metabolites in plasma and urine (glutathione and pyrimidines) and the aberrant expression of upstream gene regulators (L2HGDH, IDH2, OPLAH, and ASL) in muscle. Combined levels of L-pyroglutamic and orotic acid displayed an outstanding biomarker signature in urine with 100% sensitivity and specificity. The confirmation of systemic metabolic disarrangements in IBM and the identification of novel biomarkers reported herein unveil novel insights that require validation in larger cohorts.
    Sprache Englisch
    Erscheinungsdatum 2023-08-19
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article
    ZDB-ID 2704216-9
    ISSN 2076-3921
    ISSN 2076-3921
    DOI 10.3390/antiox12081639
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib.

    Rodríguez-Gil, Alfonso / Escamilla-Gómez, Virginia / Nufer, Melanie / Andújar-Sánchez, Félix / Lopes-Ramos, Teresa / Bejarano-García, José Antonio / García-Guerrero, Estefanía / Calderón-Cabrera, Cristina / Caballero-Velázquez, Teresa / García-Calderón, Clara Beatriz / Hernández-Díaz, Paola / Reguera-Ortega, Juan Luis / Rodríguez-Torres, Nancy / Martínez-Cibrián, Nuria / Rodríguez-Barbosa, José Ignacio / Villadiego, Javier / Pérez-Simón, José Antonio

    Scientific reports

    2022  Band 12, Heft 1, Seite(n) 8348

    Abstract: Donor derived regulatory T lymphocytes and the JAK1/2 kinase inhibitor ruxolitinib are currently being evaluated as therapeutic options in the treatment of chronic graft versus host disease (cGvHD). In this work, we aimed to determine if the combined use ...

    Abstract Donor derived regulatory T lymphocytes and the JAK1/2 kinase inhibitor ruxolitinib are currently being evaluated as therapeutic options in the treatment of chronic graft versus host disease (cGvHD). In this work, we aimed to determine if the combined use of both agents can exert a synergistic effect in the treatment of GvHD. For this purpose, we studied the effect of this combination both in vitro and in a GvHD mouse model. Our results show that ruxolitinib favors the ratio of thymic regulatory T cells to conventional T cells in culture, without affecting the suppressive capacity of these Treg. The combination of ruxolitinib with Treg showed a higher efficacy as compared to each single treatment alone in our GvHD mouse model in terms of GvHD incidence, severity and survival without hampering graft versus leukemia effect. This beneficial effect correlated with the detection in the bone marrow of recipient mice of the infused donor allogeneic Treg after the adoptive transfer.
    Mesh-Begriff(e) Animals ; Disease Models, Animal ; Graft vs Host Disease/drug therapy ; Mice ; Nitriles ; Pyrazoles ; Pyrimidines ; T-Lymphocytes, Regulatory/transplantation
    Chemische Substanzen Nitriles ; Pyrazoles ; Pyrimidines ; ruxolitinib (82S8X8XX8H)
    Sprache Englisch
    Erscheinungsdatum 2022-05-19
    Erscheinungsland England
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-022-12407-x
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang